<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8</volume><submitter>Sperle I</submitter><funding>Deutsches Zentrum für Infektionsforschung</funding><funding>Bundesministerium für Gesundheit</funding><pubmed_abstract>&lt;b>Background:&lt;/b> One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. &lt;b>Methods:&lt;/b> The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search o</pubmed_abstract><journal>Frontiers in public health</journal><pagination>424</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7493659</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.</pubmed_title><pmcid>PMC7493659</pmcid><pubmed_authors>Sperle I</pubmed_authors><pubmed_authors>Beermann S</pubmed_authors><pubmed_authors>Sarma N</pubmed_authors><pubmed_authors>Thamm R</pubmed_authors><pubmed_authors>Zimmermann R</pubmed_authors><pubmed_authors>Bremer V</pubmed_authors><pubmed_authors>Dudareva S</pubmed_authors><pubmed_authors>Cornberg M</pubmed_authors><pubmed_authors>Wedemeyer H</pubmed_authors><pubmed_authors>Steffen G</pubmed_authors><pubmed_authors>Simeonova Y</pubmed_authors><pubmed_authors>Leendertz SA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.</name><description>&lt;b>Background:&lt;/b> One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. &lt;b>Methods:&lt;/b> The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search o</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-05-29T19:38:23.496Z</modification><creation>2025-05-29T19:38:23.496Z</creation></dates><accession>S-EPMC7493659</accession><cross_references><pubmed>33014960</pubmed><doi>10.3389/fpubh.2020.00424</doi></cross_references></HashMap>